Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes - Trial NCT03018028
Access comprehensive clinical trial information for NCT03018028 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 243 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 3
Jan 10, 2017
Aug 15, 2018
Primary Outcome
Change in HbA1c (Week 26)
Summary
This trial is conducted in Asia. The aim of this trial is to investigate the dose-response
 relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide
 versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes
 mellitus
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03018028
Non-Device Trial